US 12264322
Minimal volume reprogramming of mononuclear cells
granted A61KA61K2035/124A61K35/51
Quick answer
US patent 12264322 (Minimal volume reprogramming of mononuclear cells) held by Fate Therapeutics, Inc. expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Fate Therapeutics, Inc.
- Grant date
- Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 23
- CPC classes
- A61K, A61K2035/124, A61K35/51, A61K35/545